Literature DB >> 9572497

Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer.

H Fujii1, M A Biel, W Zhou, S A Weitzman, S B Baylin, E Gabrielson.   

Abstract

HIC-1 (hypermethylated in cancer) is a candidate tumor suppressor gene which is located at 17p13.3, a region which frequently undergoes allelic loss in breast and other human cancers. HIC-1 is proposed to be commonly inactivated in human cancers by hypermethylation of a normally unmethylated dense CpG island which encompasses the entire gene. To study whether HIC-1 inactivation may be important to the development of breast cancer, we first measured methylation of the HIC-1 gene in normal breast ductal tissues from microdissected frozen breast tissues and from epithelial cells purified from mammoplasty specimens. Surprisingly, in all normal breast ductal tissues we found approximately equal amounts of densely methylated HIC-1 and completely unmethylated HIC-1. This is in contrast to most normal tissues, in which all copies of HIC-1 are completely unmethylated. We then evaluated 39 primary breast cancer tissues and found virtually complete methylation of the HIC-1 gene in 26 (67%) of the cases. We also found loss of heterozygosity at the telomeric portion of chromosomal arm 17p in 22 of the 26 cases with strongly methylated HIC-1, suggesting that loss of an unmethylated HIC-1 allele may contribute to the inactivation of HIC-1 in cells with a pre-existing methylated allele. Finally, by RNase protection analysis, HIC-1 was found to be expressed in microdissected normal breast ductal tissues and unmethylated tumors but not in tumors with hypermethylation of the HIC-1 gene. These results indicate that hypermethylation of HIC-1 and associated loss of HIC-1 expression is common in primary breast cancer. Furthermore, the HIC-1 gene is densely methylated in approximately one-half of the alleles in normal breast epithelium, which may predispose this tissue to inactivation of this gene by loss of heterozygosity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572497     DOI: 10.1038/sj.onc.1201976

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

Review 1.  RNA activation technique and its applications in cancer research.

Authors:  Xiao-Yu Wang; Long Yuan; Yan-Ling Li; Si-Jie Gan; Lin Ren; Fan Zhang; Jun Jiang; Xiao-Wei Qi
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 2.  HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.

Authors:  Capucine Fleuriel; Majid Touka; Gaylor Boulay; Cateline Guérardel; Brian R Rood; Dominique Leprince
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

Review 3.  SIRT1 and p53, effect on cancer, senescence and beyond.

Authors:  Jingjie Yi; Jianyuan Luo
Journal:  Biochim Biophys Acta       Date:  2010-05-13

Review 4.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

5.  Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex.

Authors:  Qinghong Zhang; Su-Yan Wang; Capucine Fleuriel; Dominique Leprince; Jonathan V Rocheleau; David W Piston; Richard H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-09       Impact factor: 11.205

6.  The transcription factor Hypermethylated in Cancer 1 (Hic1) regulates neural crest migration via interaction with Wnt signaling.

Authors:  Heather Ray; Chenbei Chang
Journal:  Dev Biol       Date:  2020-06-02       Impact factor: 3.582

7.  Regulation of the cyclin-dependent kinase inhibitor 1A gene (CDKN1A) by the repressor BOZF1 through inhibition of p53 acetylation and transcription factor Sp1 binding.

Authors:  Min-Kyeong Kim; Bu-Nam Jeon; Dong-In Koh; Kyung-Sup Kim; So-Yoon Park; Chae-Ok Yun; Man-Wook Hur
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

Review 8.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

9.  Epimutations, inheritance and causes of aberrant DNA methylation in cancer.

Authors:  David Mossman; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2006-05-15       Impact factor: 2.857

10.  P53 induction accompanying G2/M arrest upon knockdown of tumor suppressor HIC1 in U87MG glioma cells.

Authors:  Sanjay Kumar
Journal:  Mol Cell Biochem       Date:  2014-07-04       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.